<DOC>
	<DOCNO>NCT01194258</DOCNO>
	<brief_summary>The purpose study compare Humalog ( insulin lispro ) -recombinant human hyaluronidase PH20 ( rHuPH20 ) Novolog ( insulin aspart ) -rHuPH20 insulin lispro treatment Type 2 diabetes mellitus ( T2DM ) basal-bolus therapy .</brief_summary>
	<brief_title>Safety/Efficacy Study Subcutaneously Injected Prandial Insulins Compared Insulin Lispro Alone Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Criteria randomization study include 1 ) fast blood glucose pre-dinner glucose value range 70 140 milligram per deciliter ( mg/dL ) approximately 60 % time 7 day prior randomization ; 2 ) 90 minute 2-hour postprandial blood glucose &lt; 220 mg/dL approximately 70 % time 7 day prior randomization ; 3 ) successfully complete 3 day 10-point glucose monitoring least 4 self-monitored blood glucose value non-10-point monitoring day . Participants meet 1 criterion 4- 6-week Titration Period randomize .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Males female ≥18 year Type 2 diabetes mellitus ( T2DM ) treat insulin ≥12 month prandial insulin ( least 2 meal per day ) ≥2 month Body mass index ( BMI ) 23.0 45.0 kilogram per meter square ( kg/m^2 ) Glycosylated hemoglobin ( HbA1C ) level 7.0 8.5 % , inclusive Fasting Cpeptide &lt; 0.6 nanogram per milliliter ( ng/mL ) Willingness use insulin glargine twice day basal insulin duration study Willingness avoid use insulin infusion pump unblinded continuous glucose monitoring ( CGM ) study Known suspect allergy component study drug Exclusive use premixed insulin Use pramlintide , exenatide , and/or liraglutide within 30 day screen Use sulfonylurea within two month screen Use drug ( corticosteroid antimetabolite ) could interfere interpretation study result know cause clinically relevant interference insulin action , glucose utilization , recovery hypoglycemia , study within 30 day screen Recurrent severe hypoglycemia ( 2 episode last 6 month ) hypoglycemic unawareness , judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Type 2 diabetes</keyword>
</DOC>